Mizuho analyst Vikram Malhotra lowered the firm’s price target on Ventas (VTR) to $68 from $71 and keeps an Outperform rating on the shares. The firm says that despite healthcare real estate investment trusts’ outperformance in fiscal 2024, it continues to like the subsector into fiscal 2025, but feels “some rotation is warranted. Mizuho reiterates a positive stance on senior housing and shifted to neutral from positive on the skilled nursing facility group. It recommends rotating into life sciences as it sees venture funding improving through the year.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VTR:
- Ventas comments on master lease with Brookdale Senior Living
- Ventas price target raised to $68 from $65 at Scotiabank
- Ventas 10.6M share Spot Secondary priced at $63.90
- Ventas announces 10.6M share common stock offering
- Ventas price target raised to $79 from $66 at BofA
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
